Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Santen Pharmaceutical Co ( (JP:4536) ) has provided an announcement.
Santen Pharmaceutical Co., Ltd. announced the status of its share buyback program, having repurchased 1,332,800 common shares for a total of 2,113,806,800 yen between May 22 and May 31, 2025. This buyback is part of a broader initiative approved by the Board of Directors, which allows for the repurchase of up to 19.8 million shares, representing 5.8% of the total outstanding shares, with a maximum budget of 35 billion yen, running until November 5, 2025. This move reflects Santen’s strategic financial management and could potentially enhance shareholder value.
The most recent analyst rating on (JP:4536) stock is a Buy with a Yen1900.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company dedicated to eye health, providing products and services to patients, consumers, and medical professionals globally. With over 130 years of experience, Santen focuses on the research, development, manufacturing, and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries. The company aims to deliver significant value in the prevention, diagnosis, and treatment of eye diseases through its expertise in ophthalmology.
YTD Price Performance: 0.36%
Average Trading Volume: 1,260,665
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen547.6B
Find detailed analytics on 4536 stock on TipRanks’ Stock Analysis page.